financetom
Business
financetom
/
Business
/
Nvidia takes EU antitrust regulators to court for probing AI startup Run:ai bid
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia takes EU antitrust regulators to court for probing AI startup Run:ai bid
Feb 24, 2025 9:34 AM

BRUSSELS (Reuters) - U.S. chipmaker Nvidia ( NVDA ) has sued EU antitrust regulators for accepting an Italian request last year to scrutinise its acquisition of AI startup Run:ai, saying they had flouted an earlier court ruling restricting their merger powers on minor deals.

While the case does not have any impact on the Run:ai deal which was eventually approved by the EU competition watchdog in December last year, a ruling favouring Nvidia ( NVDA ) may further curb the regulator's merger power.

Businesses have been concerned in recent years with the European Commission flexing a rarely-used power called Article 22 to assess small deals even though these are below the EU's merger revenue threshold.

The EU executive says it is concerned about killer acquisitions in which big companies buy startups to shut them down, but companies criticise such moves as regulatory over-reach.

Europe's highest court, however, in a landmark ruling in September last year said the Commission cannot encourage or accept referrals of deals without a European dimension from national enforcers when the latter do not have the powers to examine such deals under their own national laws.

Nvidia ( NVDA ) cited the ruling in its lawsuit filed with the Luxembourg-based General Court, Europe's second-highest, according to a filing on the court website.

"The decision unlawfully accepted a referral request from the Italian Autorità Garante della Concorrenza (AGCM), regarding a transaction that fell below the EU Merger Regulation and member state merger control thresholds, based on the AGCM's exercise of loosely defined, ex post, discretionary call-in powers," Nvidia ( NVDA ) said.

It said regulators' decision to take up the Italian request breaches principles of institutional balance, legal certainty, proportionality and equal treatment.

The case is T-15/25 Nvidia ( NVDA ) v Commission.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
NextEra Energy Unusual Options Activity For September 24
NextEra Energy Unusual Options Activity For September 24
Oct 3, 2024
Investors with a lot of money to spend have taken a bullish stance on NextEra Energy . And retail traders should know. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with...
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Sanofi gets two bids valuing its consumer health unit at about $17 billion, Bloomberg News reports
Oct 3, 2024
Sept 24 (Reuters) - Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, from private equity firms Clayton Dubilier & Rice and PAI Partners, Bloomberg News reported on Tuesday. The drugmaker could decide to pursue a spinoff of the business if the bids aren't attractive, Bloomberg...
--Justice Department Sues Visa Over Alleged Antitrust Violations
--Justice Department Sues Visa Over Alleged Antitrust Violations
Oct 3, 2024
02:29 PM EDT, 09/24/2024 (MT Newswires) -- Price: 275.24, Change: -13.39, Percent Change: -4.64 ...
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Oct 3, 2024
Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc. ( REGN )‘s effort to prevent the sale of Amgen Inc ( AMGN )‘s Eylea biosimilar. Regeneron filed a notice of its appeal to the U.S. Court of Appeals for the Federal Circuit. The appeal is from the Order issued on September 23, 2024, which denied Regeneron’s request for a preliminary injunction,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved